Trial Profile
To study the mechanisms of John Cunningham virus (JCV) infection causing progressive multifocal leukoencephalopathy in multiple sclerosis patients treated with natalizumab
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Nov 2016
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics
- 22 Nov 2016 New trial record